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Abstract The aryl hydrocarbon receptor mediates the tran-
scriptional response to a variety of hydrocarbons of members of
the aryl hydrocarbon gene battery. Phenobarbital does not bind
the aryl hydrocarbon receptor with high affinity but induces, in
liver cells, expression of cytochrome P4501A. Using both wild
type and aryl hydrocarbon receptor knock out C57BL/6J mice,
we demonstrate that phenobarbital induced hnRNA, mRNA and
protein for the cytochrome P-4501A2 gene in the presence or
absence of the aryl hydrocarbon receptor. Using the DNA
binding site for the aryl hydrocarbon receptor as a probe, gel
retardation analyses showed that phenobarbital treatment
induced protein binding, regardless of the presence of the aryl
hydrocarbon receptor.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
The aryl hydrocarbon receptor (AHR) and the aryl hydro-
carbon receptor nuclear translocator (ARNT) proteins belong
to a small family of transcription factors (de¢ning the PAS
family) involved in DNA and/or ligand binding [1]. The well
established role of the AHR is to transactivate genes in re-
sponse to either xenobiotic compounds or other stimuli such
as modi¢cation of cell shape and interactions with the extra-
cellular matrix or other cells [2]. The DNA sequences recog-
nized by the heteromeric AHR-ARNT complex have been
named xenobiotic or drug response elements (XRE or DRE)
and are generally present in several copies in the 5P-£anking
region of responsive genes [3]. Following DNA binding, the
activated receptor complex allows the inductive response
through interaction with the basal transcription machinery
[4,5].
Recently, the gene coding the AHR has been knocked out
in mice by two separate groups to yield AHR3=3 homozygous
C57BL/6J mouse lines [6,7]. As expected, the inductive re-
sponse of two of the genes positively regulated by the AHR,
namely the cytochrome P4501A1 and 1A2 (CYP1A1 and
CYP1A2) genes, to AHR ligands such as polycyclic aromatic
hydrocarbons (PAH) (3-methylcholanthrene, 3-MC), was lost
in AHR3=3 mouse lines. However, expression of these genes
has also been shown to be in£uenced by xenobiotics that are
not high a⁄nity ligands, or even not at all ligands of the
receptor. Among these molecules, omeprazole, a gastric pro-
ton pump inhibitor, has recently been suggested to activate
the AHR in the absence of direct binding, possibly through
the generation of a metabolic derivative of very short half-life
[8].
Another class of molecules, typi¢ed by the barbiturate phe-
nobarbital (PB), has been shown, in several experimental sys-
tems, to activate expression of the CYP1A1 gene [9^13],
although PB mainly induces transcription of genes that are
di¡erent from those that respond to AHR ligands, including
the rat CYP2B1 and 2B2 genes [14]. For instance, PB is able
to induce a transcriptional activation of the CYP1A1 gene in
trout hepatocytes and increased CYP1A1 mRNA accumula-
tion in rat hepatocyte primary cultures or in rat hepatoma
cells [10,15]. PB is also able to act in a synergistic fashion
with 3-MC and benzanthracene, another AHR ligand, to in-
duce the CYP1A1 gene, suggesting that the barbiturate and
AHR ligands do not act through the same pathway [15,16]. In
addition, both PAHs and PB can induce glutathione S-trans-
ferases of the alpha class (GSTYK), and the molecular events
that underlie these responses are believed to be at least partly
distinct [17].
The aim of the present study was to analyze the response to
PB of CYP genes from subfamilies 1A, 2B and 3A, as well as
GSTYK in mouse liver using both wild type (wt) and
AHR3=3 mice to directly address the question of the require-
ment for a functional AHR molecule in PB induction.
2. Materials and methods
2.1. Chemicals
PB sodium salt was from CoopeŁration Pharmaceutique Franc°aise
(Melun, France), 3-MC was from Sigma (St. Quentin Fallavier,
France), poly(dI-dC) was from Pharmacia Biotech (St-Quentin-Yve-
lines, France). Acrylamide gel solution was from Appligene Oncor
(Illkirch, France). The oligonucleotides were synthesized by Genset
SA (Paris, France). M-MLV reverse transcriptase and DNase I were
from Promega (Madison, WI, USA), and Taq DNA polymerase was
from Life Technologies (Cergy Pontoise, France).
2.2. Animal housing and treatment
Mouse care was according to institutional guidelines. AHR3=3 mice
originate from homologous recombinant 129Sv-derived cells and were
FEBS 20019 27-3-98
0014-5793/98/$19.00 ß 1998 Federation of European Biochemical Societies. All rights reserved.
PII S 0 0 1 4 - 5 7 9 3 ( 9 8 ) 0 0 2 4 6 - 4
*Corresponding author. Fax: 33 (2) 99 33 62 42.
E-mail: laurent.corcos@univ-rennes1.fr
Abbreviations: AHR, aryl hydrocarbon receptor; AHR3=3, knocked
out AHR gene; Ah, aryl hydrocarbon; CYP, cytochrome P450;
ARNT, aryl hydrocarbon receptor nuclear translocator; PAS, Per-
ARNT-Sim; XRE, xenobiotic response element; DRE, drug response
element; 3-MC, 3-methylcholanthrene; PB, phenobarbital ; PAH,
polycyclic aromatic hydrocarbon; wt, wild type; GSTYK, glutathione
S-transferase alpha class; EDTA, ethylene diamine tetraacetic acid;
TBE, Tris-borate-EDTA
FEBS 20019 FEBS Letters 425 (1998) 293^297
derived in collaboration with one of us [6]. Chimeric males were
initially backcrossed to C57BL/6J females. For the purpose of this
study, several additional rounds of backcrossing were performed in
our animal facility to increase the C57BL/6J genetic background in
heterozygous breeders and generate the homozygous mutant animals
used. Wt C57BL/6J used as controls were from IFFA-CREDO (Les
Oncins, France). Mice were housed under conventional conditions in
individual cages. Animal sampling was designed to reduce the in£u-
ence of interfering factors (parental imprinting, litter speci¢city). Mice
received a regular chow diet. Water and food were available ad libi-
tum.
2.3. RNA extraction and hybridization
Total RNA was isolated according to [18] from fresh liver biopsies
homogenized in Trizol solution (Life Technologies, Cergy Pontoise,
France) using a tissue homogenizer (Ika, Jena, Germany) with a 7 mm
diameter probe. DNase I-treated hnRNAs for the CYP1A2 gene were
analyzed by semi-quantitative reverse transcriptase (RT)-PCR using
primers from intron B (forward primer: 5P-TGGGGTTATGG-
GAAAGAAGGG-3P) and intron C (reverse primer: 5P-CACACCTT-
GATCTTAGGGCAGG-3P), as described [19]. PCR products were
separated on agarose gels, transferred onto nylon membranes (Hy-
bond N, Amersham, Evry, France) and hybridized with a mouse
CYP1A2 probe. Cytoplasmic RNAs were resolved on denaturing
gels, transferred to Hybond N membranes (Amersham, Evry, France)
and hybridized as described [20] sequentially to full-length cDNA
probes for the mouse CYP1A2, the mouse CYP2B9, the rabbit
CYP3A, the mouse GSTYK, the mouse GAPDH and an oligonucleo-
tide probe for the 18S ribosomal RNA. Hybridization signals were
standardized to that of GAPDH which was una¡ected by the various
treatment conditions, by using the Densylab imaging software (Micro-
vision Instruments, Evry, France). Equivalent RNA loading and in-
tegrity were demonstrated by ethidium bromide staining of the gels
and hybridization to the 18S oligonucleotide probe.
2.4. Western blot analysis
Liver microsomes were prepared according to standard procedures.
Proteins in microsomal samples were quanti¢ed using the reagent
from Pierce (Rockford, IL, USA). 8 Wg of protein was loaded in
each lane and separated in 7.5% polyacrylamide gels. Samples were
electrophoretically blotted onto nitrocellulose membranes (Optitran
BA-S 85, Schleicher and Schuell, Dassel, Germany) before saturation
with milk proteins. Primary rabbit antibodies against CYP1A1 and
CYP1A2 (a gift from Dr. F.J. Gonzalez, National Institute of Health,
Bethesda, MA, YSA) were revealed using a peroxidase-conjugated
antibody (Sigma, St. Quentin Fallavier, France) and a chemilumines-
cent reagent (Pierce, Rockford, IL, USA) following autoradiography.
2.5. Gel retardation assays
Nuclear extracts were isolated as described [21]. Binding reactions
using 4 Wg of nuclear protein samples were carried out in a 15 Wl
volume containing 1 mM sodium phosphate (pH 7.5), 0.1 mM
EDTA, 0.5 mM dithiothreitol, 10% (v/v) glycerol, 2 Wg poly(dI-dC),
1 mM MgCl2, 10 mM spermidine, 0.1^0.2 ng of 32P-labeled 5P-end
oligonucleotide. The XRE (DRE3) oligonucleotide probe had the fol-
lowing sequence: 5P-GATCTGGCTCTTCTCAC-3P. 4 Wg nuclear
protein was added to the reaction mixture and incubated for 30 min
at 24‡C. The DNA-protein complexes were resolved on 6% acryl-
amide gels in 0.5UTBE (45 mM Tris-borate, 1.25 mM EDTA) at
22 mAmp for 2 h. The gels were then ¢xed, dried, and subjected to
autoradiography.
3. Results and discussion
3.1. PB induces CYP1A2 mRNA in the liver of both wt
and AHR3=3 mice
Male mice from the C57BL/6J strain were treated for 12 h
with a single intraperitoneal injection of either sodium PB
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Fig. 1. RNA blot analysis of the CYP1A1, CYP1A2 and CYP2B9/10 genes in wt and AHR3=3 mice. 10 Wg of total RNA from three animals
from the same treatment group was resolved on denaturing gels. Following transfer to nylon membranes, hybridization experiments were per-
formed as described in Section 2. OKUT, OKMC and OKPB stand for untreated, 3-MC-treated and PB-treated wt animals, respectively.
KOUT, KOMC and KOPB stand for untreated, 3-MC-treated and PB-treated AHR3=3 animals, respectively. A low and a very low basal level
were detected with the CYP2B9/10 and CYP1A2 cDNA probes, respectively, on longer exposure of RNA ¢lters.
Table 1
Induction factors for CYP1A1, CYP1A2, CYP2B9/10, CYP3A11/13 and GSTYK mRNA levels in wt and AHR3=3 mice
OKUT KOUT OKMC KOMC OKPB KOPB
CYP1A1a na na +++ na na na
CYP1A2 1 þ 0.2 6 1 20 þ 3 6 1 3 þ 1 s 5 þ 2
CYP2B9/10 1 þ 0.1 1 þ 0.1 1 þ 0.2 1 þ 0.1 22 þ 2 21 þ 3
CYP3A11/13 1 þ 0.1 1 þ 0.2 1 þ 0.2 1 þ 0.1 17 þ 3 17 þ 2
GSTYK 1 þ 0.3 1 þ 0.2 3 þ 0.2 1 þ 0.3 5 þ 2 5 þ 1
The induction factors represent the mean þ standard deviation from three separate RNA samples under each condition, and were determined by
comparison with the respective control (i.e. OKPB and OKMC versus OKUT; KOPB and KOMC versus KOUT). OKUT, OKMC and OKPB
stand for untreated, 3-MC-treated and PB-treated wt animals, respectively. KOUT, KOMC and KOPB stand for untreated, 3-MC-treated and PB-
treated AHR3=3 animals, respectively. For a given probe, basal mRNA levels were essentially identical between all individuals, except for the
CYP1A2 probe which showed a strongly decreased basal level in AHR3=3 mice as compared to wt mice.
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(100 mg/kg) or 3-MC (80 mg/kg) and the livers were promptly
removed and frozen or used to prepare total RNA 12 h later.
As shown in Fig. 1, PB readily induced CYP1A2 mRNA (2
kbp long), but not CYP1A1 (3 kbp long), in both wt and
AHR3=3 mice, despite the lower basal level of this message
in AHR3=3 mice. We have made similar observations at later
time points and a lower PB dose (3 days and 50 mg/kg, data
not shown). However, 3-MC had no detectable e¡ect in
AHR3=3 mice, although it induced both CYP1A1 and
CYP1A2 mRNAs in wt mice, as expected. In addition, PB
induction of known PB-responsive genes was una¡ected in the
AHR3=3 animals (Table 1), in agreement with the notion that
a functional AHR is not required for the PB response of
either CYP2B or CYP3A genes in the liver [14]. In addition,
the 3-MC induction, but not the PB induction of the GSTYK
genes was abolished in AHR3=3 mice.
These results unambiguously demonstrate that PB induc-
tion of the CYP1A2 and the GSTYK genes in mice does
not require a functional AHR. In agreement with these ob-
servations, it was recently reported that piperonyl butoxide
and acenaphthylene induce CYP1A2 mRNA in AHR3=3 an-
imals from the same origin [19].
3.2. PB induces CYP1A2 hnRNA in both wt and
AHR3=3 mice
A survey of hnRNA levels by speci¢c RT-PCR using a
combination of primers from two introns has been proposed
as a substitute to nuclear run on assays. Although the method
does not determine the actual level of newly synthesized
mRNA, it re£ects both transcriptional and post-transcription-
al processing, but not mRNA stabilization or destabilization
like RNA blotting experiments would [22]. The method ap-
plied to the mouse CYP1A2 gene has been published previ-
ously [19]. Using this strategy, we demonstrated that both PB
and 3-MC strongly induced CYP1A2 nuclear RNA in wt
mice, but only PB also induced this primary transcript in
AHR3=3 animals (Fig. 2). Control experiments using speci¢c
CYP1A1 primer pairs showed that 3-MC, but not PB,
strongly induced CYP1A1 hnRNA, in agreement with the
results from RNA blotting experiments (see above), and this
only in wt mice (data not shown).
3.3. The CYP1A2 protein is induced by PB in both wt
and AHR3=3 mice
Microsomal protein samples from the same animals as used
above were prepared and analyzed as described in Section 2.
The results presented in Fig. 3 show that only the CYP1A2
protein was detectable under basal conditions, and was
strongly reduced in AHR3=3 mice, as expected [6]. 3-MC
induced both the CYP1A1 and the CYP1A2 proteins in wt
animals, but had no e¡ect in AHR3=3 mice. However, PB
induced the CYP1A2, but not the CYP1A1 protein, in both
wt and AHR3=3 mice. The PB-induced protein level was
somewhat lower than that obtained in wt mice, most probably
because of a decreased basal level. It could also be that there
is a partial requirement for the AHR. These results show that
PB is able to induce the CYP1A2 protein in the liver in both
the presence and the absence of the AHR, in agreement with
its e¡ects on CYP1A2 mRNA levels.
3.4. AHR gene disruption does not prevent protein binding
to the XRE
Nuclear protein extracts were used to look at protein bind-
ing to one XRE element in either wt or AHR3=3 mice treated
or not with PB or 3-MC. Our results show that a speci¢c
DNA binding activity could be detected in wt animals treated
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Fig. 2. CYP1A2 hnRNA analysis in wt and AHR3=3 mice. Reverse transcribed hnRNAs (corresponding to 125 ng of total RNA) from three
animals from the same treatment group were subjected to PCR ampli¢cation for various cycle numbers in a 50 Wl volume. 5 Wl was separated
on a 0.8% agarose gel, transferred onto nylon membranes and hybridized with a CYP1A2 cDNA probe. UT, PB and MC stand for untreated,
3-MC-treated and PB-treated animals, respectively. The expected 435 bp CYP1A2-derived cDNA fragment [19] was visualized following autora-
diography.
Fig. 3. Western blot analysis of the CYP1A1 and CYP1A2 proteins in wt and AHR3=3 mice. 8 Wg of microsomal proteins from three animals
from the same treatment group was resolved on denaturing acrylamide gels. Following transfer to nitrocellulose membranes, antibody recogni-
tion experiments were performed as described in Section 2.
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or not with 3-MC or PB (Fig. 4). However, a much lower
DNA binding activity was detected in AHR3=3 mice un-
treated or treated with 3-MC. This observation could explain,
at least partly, the decreased constitutive expression level of
the CYP1A2 mRNA in AHR3=3 animals and the lack of
responsiveness to 3-MC of both the CYP1A1 and 1A2 genes
in these animals. Strikingly, a strong binding activity was
observed following PB treatment of wt mice and remained
similar in intensity in AHR3=3 mice, suggesting that the ma-
jor proteins binding to the XRE in response to PB are distinct
from the AHR. Therefore, it appears that the AHR is indeed
able to bind to the XRE sequence, but, in addition, in its
absence, a protein(s) can interact with this motif as a result
of PB treatment. One or more of the recently described new
PAS proteins could be involved in this DNA recognition po-
tential in mice [23].
Although indicative of a possible role of PB through the
XRE motif, these results do not provide any clue as to
whether PB acts through this DNA sequence element to in-
duce expression of the CYP1A2 gene. In addition, transfec-
tion experiments of a construct containing two copies of the
XRE sequence driving expression of the chloramphenicol ace-
tyltransferase gene failed to demonstrate PB-inducible expres-
sion in primary hepatocyte cultures (data not shown). This
absence of detectable PB responsiveness is most likely due
to the low sensitivity of the assay. Alternatively, it is possible
that the presumptive XRE motifs from the CYP1A promoter
region cannot be e⁄ciently transactivated by PB when re-
moved from the context of the native promoter. Furthermore,
1843 bp of the immediately upstream region of the mouse
CYP1A2 gene failed to demonstrate the presence of functional
AHR-ligand responsive sequences upon transfection of mouse
hepatoma cells [24]. This observation suggests that the DNA
sequences present in this portion of the CYP1A2 gene locus
either do not contain functional XRE sequences or lack other
structural determinants. Interestingly, it has also been pro-
posed that induction of the human CYP1A2 gene by 3-MC
might require both a XRE-like sequence centered around po-
sition 32496 bp and an AP1 binding site located at 32031 bp
upstream of the transcriptional start site [25]. In this respect,
AP1-related proteins have been suggested to play a positive
role in the PB induction of the rat CYP2B2 and mouse GSTYK
genes in view of the ability of the barbiturate to induce in-
creased band shift of nuclear proteins with the AP1 DNA
binding site, and to stimulate transcription in transient trans-
fection assays with the GSTYK promoter [17].
In conclusion, our results show that PB is able to increase
the levels of CYP1A2 ^ but not CYP1A1 ^ hnRNA, mRNA
and protein in C57BL/6J mice irrespective of the presence of a
functional AHR. Although it is formally possible that this
receptor could be required, directly or indirectly, for the PB
response in wt but not in AHR3=3 mice, the simplest hypoth-
esis would certainly argue that PB induction of the CYP1A2
gene does not require the AHR.
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and KOPB stand for untreated, 3-MC-treated and PB-treated
AHR3=3 animals, respectively.
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